CoChat
Sign Up
Cited by 267Attention Deficit Hyperactivity DisorderPharmacology and Obesity TreatmentPharmaceutical studies and practices

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

A Randomized, Placebo-Controlled Trial of OROS Methylphenidate in Adults with Attention-Deficit/Hyperactivity Disorder

Biederman, Joseph, Mick, Eric, Surman, Craig, Doyle, Robert, Hammerness, Paul, Harpold, Theresa, Dunkel, Stephanie, Dougherty, Meghan, Aleardi, Megan, Spencer, Thomas·2006·Biological Psychiatry
DOI 10.1016/j.biopsych.2005.09.011
Open this paper in CoChat — free account

Abstract

Background The objective of this study was to evaluate the safety and efficacy of once-daily OROS methylphenidate (MPH) in the treatment of adults with DSM-IV attention-deficit/hyperactivity disorder (ADHD). Methods We conducted a randomized, 6-week, placebo-controlled, parallel-design study of OROS MPH in 141 adult subjects with DSM-IV ADHD, using standardized instruments for diagnosis. OROS MPH or placebo was initiated at 36 mg/day and titrated to optimal response, depending on efficacy and tolerability, up to 1.3 mg/kg/day. Results Treatment with OROS MPH was associated with clinically and statistically significant reductions in DSM-IV symptoms of inattention and hyperactivity/impulsivity relative to subjects treated with placebo. At endpoint, 66% of subjects (n = 44) receiving OROS MPH and 39% of subjects (n = 29) [corrected] receiving placebo attained our a priori definition of response of much or very much improved on the Clinical Global Impression-Improvement scale plus a >30% reduction in Adult ADHD Investigator System Report Scale score. OROS MPH was associated with small but statistically significant increases in systolic blood pressure (3.5 +/- 11.8 mm Hg), diastolic blood pressure (4.0 +/- 8.5 mm Hg), and heart rate (4.5 +/- 10.5 bpm). Conclusions These results show that treatment with OROS MPH in daily doses of up to 1.3 mg/kg/day was effective in the treatment of adults with ADHD. Because of the potential for increases in blood pressure and heart rate, subjects receiving treatment with MPH should be monitored for changes in blood pressure parameters during treatment.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.biopsych.2005.09.011

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 29 references

Research works printed but not linked: 2

  1. 1985, CGI (Clinical Global Impression) Scale—NIMH, Psychopharmacol Bull, 21, 839
  2. Spencer, 2004, Diagnostic approaches to adult attention-deficit/hyperactivity disorder, Prim Psychiatry, 11, 49

Cited by

Sorted by citations

Items 101–200 of 267

Related

See all

Metadata

Authors
Biederman, J., Mick, E., Surman, C., Doyle, R., Hammerness, P., Harpold, T., Dunkel, S., Dougherty, M., Aleardi, M., & Spencer, T.
Affiliations
Harvard University (US)
Corresponding author
Biederman, Joseph
ORCID
Venue
Biological Psychiatry
Publisher
Elsevier BV
Published
2006-05
Volume
59
Issue
9
Pages
829-835
ISSN
0006-3223 (ISSN-L)
DOI
10.1016/j.biopsych.2005.09.011
OpenAlex
W2164676183
Cited by
267
References
29
Citations by year
2026: 4 · 2025: 9 · 2024: 6 · 2023: 8 · 2022: 10 · 2021: 2 · 2020: 9 · 2019: 4 · 2018: 7 · 2017: 5 · 2016: 14 · 2015: 7 · 2014: 18 · 2013: 16 · 2012: 20
FWCI
11.15
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Biological Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
Keywords
OROS methylphenidate, attention deficit hyperactivity disorder, adult ADHD, sustained-release formulation, inattention, hyperactivity/impulsivity, blood pressure, heart rate, drug safety and efficacy, dose titration
MeSH terms
Adult, Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity, Cardiovascular System, Dose-Response Relationship, Drug, Double-Blind Method, Drug Evaluation, Female, Follow-Up Studies, Humans, Male, Methylphenidate, Middle Aged, Psychiatric Status Rating Scales, Chi-Square Distribution, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review